|
Construction and Empirical Research of a Risk Prediction Model for Preventing Lower Extremity Arteriosclerosis Obliterans in Diabetic Patients Based on the HAPA Model
RECRUITINGN/ASponsored by Second Affiliated Hospital of Nanchang University
Actively Recruiting
PhaseN/A
SponsorSecond Affiliated Hospital of Nanchang University
Started2025-04-15
Est. completion2027-10-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07881588
Summary
In this study, Logistic regression analysis was used to construct a risk prediction model for ASO in diabetic patients. Guided by the HAPA model, a nursing intervention plan for preventing ASO in diabetic patients was constructed and verified, with the aim of reducing the occurrence of ASO in diabetic patients and providing a reference for improving the quality of life of diabetic patients in clinical practice
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Meet the clinical diagnostic criteria for type 2 diabetes; * Age ≥18 years old; * The patient is conscious, has no language communication barriers, and has certain reading and writing abilities. * The patient or caregiver can use smart devices. * Informed consent and voluntary participation. Exclusion Criteria: * Those with severe audio-visual or cognitive impairments; * Combined with other serious physical diseases, such as malignant tumors, etc. * Have a history of mental illness; * Patients who already have lower extremity arterial disease.
Conditions3
DiabetesDiabetes MellitusPeripheral Arterial Disease
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorSecond Affiliated Hospital of Nanchang University
Started2025-04-15
Est. completion2027-10-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07881588